

May 19, 2026

To,
The Listing Department,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai- 400 001
Scrip Code: 543349

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C-1,
G-Block, Bandra Kurla Complex,
Mumbai -400051
NSE Symbol: ACUTAAS

Subject: Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 – Change in status of Acutaas Chemicals Electrolytes Private Limited from “Wholly owned Subsidiary” to “Subsidiary” of Acutaas Chemicals Limited (“Company”)

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we wish to inform you that the Board of Directors of **Acutaas Chemicals Electrolytes Private Limited (“ACEPL”)**, a wholly owned subsidiary of **Acutaas Chemicals Limited (“Company”)**, at its meeting held on May 19, 2026, has approved the allotment of 1,111 number of equity shares of face value of Rs. 10 (Rupees Ten Only) each at an issue price of Rs. 52,490/- per share (including premium of Rs. 52,480/- per share) on partly paid-up preferential basis by way of private placement to an Identified Investor - A.R.Z Pharma Ltd.

Consequent to the said allotment, the shareholding of the Company in ACEPL stands reduced from 100% to 90%. Accordingly, ACEPL has ceased to be a wholly owned subsidiary of the Company and shall continue to remain a subsidiary of the Company with effect from May 19, 2026. The aforesaid dilution of shareholding does not result in any change in the management control of ACEPL, and ACEPL shall continue to be under the control and management of the Company. Further, we would further like to clarify that the number of equity shares held by the Company in ACEPL remains unchanged.

The details as required under Regulation 30 of SEBI LODR Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed herewith as Annexure – A. The aforesaid information is being made available on the website of the Company at www.acutaas.com. Kindly take the same on your record.

Yours faithfully,
For, **ACUTAAS CHEMICALS LIMITED**

CS Ekta Kumari Srivastava
Company Secretary & Compliance Officer



ANNEXURE -A

**Disclosure Pursuant to Regulation 30 of SEBI LODR Regulations read with SEBI Master Circular
HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026**

SR. NO.	PARTICULARS	DETAILS				
1.	Name of the Subsidiary	Acutaas Chemicals Electrolytes Private Limited ("ACEPL")				
2.	Type of securities proposed to be issued (viz. equity shares, convertibles etc.);	Equity shares of face value of Rs. 10/- each at a share premium of Rs. 52,480/- per share.				
3.	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.);	Preferential issue of shares by way of private placement				
4.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	<p>Total 1,111 equity shares of face value of Rs. 10/- each at a share premium of Rs. 52,480/- per equity share has been issued on partly paid-up basis as per the below schedule:</p> <table border="1"> <tbody> <tr> <td>On application cum allotment (25% has been called up).</td> <td>Rs. 1,45,79,097.50 (Rupees One crore Forty-Five Lakhs Seventy-Nine Thousand Ninety-Seven and Fifty paise only)</td> </tr> <tr> <td>On 1st & Final Call (75% to be called up on or before May 2, 2027) i.e. within twelve months of the issuance of equity shares.</td> <td>Rs. 4,37,37,292.50 (Rupees Four Crore Thirty-Seven Lakhs Thirty-Seven Thousand Two Hundred Ninety-Two and Fifty paise only)</td> </tr> </tbody> </table>	On application cum allotment (25% has been called up).	Rs. 1,45,79,097.50 (Rupees One crore Forty-Five Lakhs Seventy-Nine Thousand Ninety-Seven and Fifty paise only)	On 1 st & Final Call (75% to be called up on or before May 2, 2027) i.e. within twelve months of the issuance of equity shares.	Rs. 4,37,37,292.50 (Rupees Four Crore Thirty-Seven Lakhs Thirty-Seven Thousand Two Hundred Ninety-Two and Fifty paise only)
On application cum allotment (25% has been called up).	Rs. 1,45,79,097.50 (Rupees One crore Forty-Five Lakhs Seventy-Nine Thousand Ninety-Seven and Fifty paise only)					
On 1 st & Final Call (75% to be called up on or before May 2, 2027) i.e. within twelve months of the issuance of equity shares.	Rs. 4,37,37,292.50 (Rupees Four Crore Thirty-Seven Lakhs Thirty-Seven Thousand Two Hundred Ninety-Two and Fifty paise only)					
5.	<p>in case of preferential issue the listed entity shall disclose the following additional details to the stock exchange(s):</p> <p>i) names of the investors;</p> <p>ii) post allotment of securities - outcome of the subscription, issue price / allotted price (in case of convertibles), number of investors</p> <p>iii) in case of convertibles - intimation</p>	<p>Name of Investor: A.R.Z Pharma Ltd. having its office at St. Netanya, Israel.</p> <p>Issue Price: Rs. 52,490/- per share (including share premium of Rs. 52,480/- per share) basis valuation report as of March 31, 2026 furnished by Registered Valuer in India.</p> <p>Number of Shares Allotted: 1,111 equity shares on partly paid-up basis.</p> <p>Number of Investors: 1</p>				

	on conversion of securities or on lapse of the tenure of the instrument;	Conversion of Securities: Not Applicable
6.	Details and reasons for restructuring	ACEPL, a wholly owned subsidiary of Acutaas Chemicals Limited ('the Company'), has issued partly paid-up equity shares on preferential basis by way of private placement to A.R.Z Pharma Ltd.
7.	Quantitative and/or qualitative effect of restructuring	ACEPL has ceased to be a wholly owned subsidiary of the Company; however, it shall continue to remain a subsidiary of the Company.
8.	Details of benefit, if any, to the Promoter/ Promoter group/ group companies from such proposed restructuring.	Nil
9.	Brief details of change in shareholding pattern	<p>Pre-Transaction Shareholding Acutaas Chemicals Limited – 10,000 Equity Shares (100%)</p> <p>Post-Transaction Shareholding Acutaas Chemicals Limited – 10,000 Equity Shares (90%) A.R.Z. Pharma Ltd. – 1,111 Equity Shares (10%)</p>

